Scholar Rock Holding Corp
Scholar Rock Holding Corp is a U.S.-based biotechnology company focused on discovering and developing medicines that modulate growth factor signaling for severe diseases. Its lead programs center on apitegromab and other anti-myostatin candidates for neuromuscular disorders, with development, manufacturing, and future commercialization activities organized through third-party partners and internal research capabilities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApitegromab and related clinical-stage development for SMA and adjacent neuromuscular uses.
Anti-myostatin and other antibody-based programs under preclinical and clinical development.
Proprietary antibody discovery and optimization capabilities used to generate new candidates.
Clinical trial execution, regulatory filings, and supporting development work for product candidates.
Customers
Scholar Rock’s direct end customers, if its products are approved, are patients with rare neuromuscular diseases and the physicians who treat them. In practice, commercialization depends on neurologists, specialty clinics, hospitals, and third-party payors that determine prescribing, access, and reimbursement. The company also relies on contract manufacturers, research vendors, and potential commercial partners to support development and launch activities.
They would use apitegromab if approved to treat spinal muscular atrophy and related neuromuscular conditions.
They determine coverage, reimbursement, and formulary access for high-cost specialty biologics.
They diagnose, monitor, and administer therapies for patients in the target disease areas.
They provide discovery, clinical manufacturing, and development services under outsourced arrangements.
Strategy
The company’s strategy is to advance apitegromab through regulatory approval and build the commercial infrastructure needed for launch in neuromuscular disease. It is also broadening its pipeline around anti-myostatin biology while relying on outsourced manufacturing and selective external partners to scale efficiently.
Approval is the key value-creation step and the basis for first product revenue.
The company needs sales, market access, medical affairs, and distribution capabilities to launch.
A broader portfolio reduces dependence on a single lead asset and extends the platform.
Geography
Scholar Rock is headquartered in the United States and develops therapies for global markets, with commercialization planning in both the U.S. and Europe. The company has specifically referenced launch preparation in Germany as part of its European build-out, while clinical and regulatory work spans U.S. and European agencies. Its outsourced manufacturing and development model also creates exposure to third-party suppliers and service providers across multiple jurisdictions.
Risks
Scholar Rock faces the classic biotech risk stack: clinical failure, regulatory delay, and uncertainty around eventual commercialization. Because it has no product sales history and depends on third parties for manufacturing and development, execution risk, reimbursement risk, and financing needs are all material.
- Clinical development failureImpact: CriticalLikelihood: Medium
Lead assets must prove efficacy and safety in pivotal and follow-on studies before approval.
Exposure - Regulatory delay or rejectionImpact: HighLikelihood: Medium
FDA and EMA decisions determine whether the company can commercialize its lead product.
Exposure: BLA/MAA review and post-review requirements
- Commercialization execution riskImpact: HighLikelihood: Medium
The company has limited sales and distribution experience and must build capabilities or partner.
Exposure: U.S. and European launch readiness
- Reimbursement and pricing pressureImpact: HighLikelihood: Medium
Specialty biologics depend on third-party payor coverage and favorable access terms.
Exposure: Rare disease market access
- Manufacturing and supply chain dependenceImpact: MediumLikelihood: Medium
All clinical manufacturing is outsourced, increasing reliance on third-party capacity and quality.
Exposure: Clinical supply and future commercial supply
Accounting
Judgemental itemsClinical trials, manufacturing, and discovery costs are expensed as incurred and drive reported losses.
Impact: Affects operating loss and comparability across periods
Equity awards and modifications can create large non-cash G&A charges.
Impact: Can materially affect reported operating expense
The company must estimate how long existing cash will fund operations and future trials.
Impact: Important for going-concern and financing analysis
Any future partner payments, milestones, or licenses may require judgment on timing and classification.
Impact: Could affect revenue or other income recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
AbCellera Biologics Inc.
ABCL · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Skye Bioscience, Inc.
SKYE · Pharmaceutical Preparations
Abpro Holdings, Inc.
ABPO · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026